Literature DB >> 12424008

Defective glycosylation in muscular dystrophy.

Francesco Muntoni1, Martin Brockington, Derek J Blake, Silvia Torelli, Susan C Brown.   

Abstract

CONTEXT: Over the past 15 years the causative genes of several inherited muscular dystrophies have been identified. These genes encode sarcolemmal, extracellular matrix, sarcomeric, and nuclear envelope proteins. Although the post-translational processing of muscle proteins has a significant role in their correct assembly and function, these processes have not been shown to be primarily involved in the pathogenesis of muscular dystrophies until recently. In the past 18 months, four different forms of inherited muscular dystrophy in human beings have been associated with mutations in genes encoding for putative glycosyltransferases. Aberrant glycosylation of alpha-dystroglycan, an external membrane protein expressed in muscle, brain, and other tissues, is a common feature in these disorders. alpha-dystroglycan is highly glycosylated, its sugar components varying in different tissues and controlling its interaction with extracellular matrix partners. Disrupted glycosylation of alpha-dystroglycan results in a loss of these interactions, giving rise to both progressive muscle degeneration and abnormal neuronal migration in the brain. STARTING POINT: Kevin Campbell and colleagues have recently demonstrated that patients with muscle-eye-brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD), as well as the myodystrophy (myd) mouse, have an abnormally glycosyated form of alpha-dystroglycan (Nature 2002; 418: 417-22 and 422-25). The abnormally glycosylated protein did not bind to three of its extracellular matrix ligands, laminin alpha2 chain, agrin, and neurexin. The investigators also showed that a neuronal migration disorder occurs in both the myd mouse and in a brain-restricted alpha-dystroglycan knock-out mouse that is similar to that seen in patients with MEB and FCMD. These results identify alpha-dystroglycan as having an essential role in both muscle and brain development and function. WHERE NEXT: Emphasis is moving away from identifying the protein components of the muscle fibre that are involved in muscular dystrophies towards the post-translational processing of proteins and the enzymes involved in these modifications. This opens up new avenues of research. Abnormal glycosylation of alpha-dystroglycan may underlie other as yet uncharacterised forms of muscular dystrophy and neuronal migration disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424008     DOI: 10.1016/S0140-6736(02)11397-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  Dissecting muscle and neuronal disorders in a Drosophila model of muscular dystrophy.

Authors:  Halyna R Shcherbata; Andriy S Yatsenko; Larissa Patterson; Vanita D Sood; Uri Nudel; David Yaffe; David Baker; Hannele Ruohola-Baker
Journal:  EMBO J       Date:  2007-01-11       Impact factor: 11.598

Review 2.  Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.

Authors:  Paul T Martin
Journal:  Nat Clin Pract Neurol       Date:  2006-04

3.  Glycoproteomic characterization of recombinant mouse α-dystroglycan.

Authors:  Rebecca Harrison; Paul G Hitchen; Maria Panico; Howard R Morris; David Mekhaiel; Richard J Pleass; Anne Dell; Jane E Hewitt; Stuart M Haslam
Journal:  Glycobiology       Date:  2012-01-11       Impact factor: 4.313

4.  Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.

Authors:  Michael S Rafii; Hiroki Hagiwara; Mary Lynn Mercado; Neung S Seo; Tianshun Xu; Tracey Dugan; Rick T Owens; Magnus Hook; David J McQuillan; Marian F Young; Justin R Fallon
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

5.  Cardiac involvement in limb-girdle muscular dystrophy 2I : conventional cardiac diagnostic and cardiovascular magnetic resonance.

Authors:  C Gaul; M Deschauer; C Tempelmann; S Vielhaber; H U Klein; H J Heinze; S Zierz; F Grothues
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

Review 6.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

7.  Merosin-deficient congenital muscular dystrophy (CMD): a study of 25 Brazilian patients using MRI.

Authors:  Claudia C Leite; Leandro T Lucato; Maria G M Martin; Lucio G Ferreira; Maria B D Resende; Mary S Carvalho; Suely K N Marie; J Randy Jinkins; Umbertina C Reed
Journal:  Pediatr Radiol       Date:  2005-03-05

8.  Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members.

Authors:  Jochen Herms; Brigitte Anliker; Sabine Heber; Sabine Ring; Martin Fuhrmann; Hans Kretzschmar; Sangram Sisodia; Ulrike Müller
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

9.  New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype.

Authors:  Te-Cheng Pan; Rui-Zhu Zhang; Dominick G Sudano; Suely K Marie; Carsten G Bönnemann; Mon-Li Chu
Journal:  Am J Hum Genet       Date:  2003-07-01       Impact factor: 11.025

10.  Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!

Authors:  J Jaeken
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.